Estland - estisk - Ravimiamet

menarini international operations luxembourg s.a. - deksketoprofeen - suukaudne lahus kotikeses - 25mg 4tk; 25mg 20tk; 25mg 10tk

Estland - estisk - Ravimiamet

menarini international operations luxembourg s.a. - deksketoprofeen - suukaudse lahuse graanulid - 12,5mg 100kott; 12,5mg 50kott; 12,5mg 30kott; 12,5mg 500kott; 12,5mg 10kott; 12,5mg 2kott; 12,5mg 20kott

Estland - estisk - Ravimiamet

menarini international operations luxembourg s.a. - deksketoprofeen - suukaudse lahuse graanulid - 12,5mg 100kott; 12,5mg 50kott; 12,5mg 30kott; 12,5mg 20kott; 12,5mg 10kott; 12,5mg 2kott

Estland - estisk - Ravimiamet

takeda pharmaceuticals international ag ireland branch - lantaan - närimistablett - 750mg 90tk; 750mg 30tk; 750mg 45tk; 750mg 75tk

Estland - estisk - Ravimiamet

menarini international operations luxembourg s.a. - deksketoprofeen - suukaudse lahuse graanulid - 25mg 10tk; 25mg 100tk; 25mg 50tk; 25mg 500tk; 25mg 20tk; 25mg 40tk; 25mg 2tk

Estland - estisk - Ravimiamet

takeda pharmaceuticals international ag ireland branch - lantaan - närimistablett - 500mg 45tk; 500mg 200tk; 500mg 100tk; 500mg 20tk; 500mg 90tk

Estland - estisk - Ravimiamet

takeda pharmaceuticals international ag ireland branch - lantaan - suukaudne pulber - 750mg 90tk

Estland - estisk - Ravimiamet

sintetica gmbh - fenüülefriin - süste-/infusioonilahus - 0,1mg 1ml 5ml 10tk; 0,1mg 1ml 50ml 1tk

Den europeiske union - estisk - EMA (European Medicines Agency)

samsung bioepis nl b.v. - bevatsizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastilised ained - onbevzi in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. onbevzi in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. lisateavet inimese epidermaalse kasvufaktori retseptori 2 (her2) seisundi kohta vt palun 5. jaotisest. onbevzi in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with onbevzi in combination with capecitabine. her2 staatuse kohta lisateabe saamiseks lugege palun 5. jaotist. onbevzi, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. onbevzi, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations. onbevzi in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. onbevzi, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer. onbevzi, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. onbevzi, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. onbevzi, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

Estland - estisk - Ravimiamet

menarini international operations luxembourg s.a. - deksketoprofeen - graanulid kotikeses - 25mg 20tk; 25mg 4tk; 25mg 500tk; 25mg 100tk; 25mg 50tk; 25mg 30tk; 25mg 10tk; 25mg 2tk